Roche, AC Immune's tau-blocking drug flops in Alzheimer's as biotech's shares halved

Blocking tau appears to be just as fruitless as clearing amyloid buildup when it comes to helping Alzheimer’s disease (AD) patients.

That’s the top-line verdict, anyway, after another setback in the field, this time from the phase 2 Tauriel trial of Roche and partner AC Immune’s anti-tau antibody, semorinemab, in early (prodromal to mild) AD.